Connect Biopharma’s (CNTB) Buy Rating Reaffirmed at HC Wainwright

Connect Biopharma (NASDAQ:CNTB)‘s stock had its “buy” rating reaffirmed by research analysts at HC Wainwright in a note issued to investors on Monday,Benzinga reports. They currently have a $8.00 price target on the stock.

Connect Biopharma Trading Up 4.0 %

Shares of CNTB stock opened at $0.57 on Monday. The business’s 50 day simple moving average is $0.88 and its 200 day simple moving average is $1.06. Connect Biopharma has a one year low of $0.55 and a one year high of $2.66.

Institutional Investors Weigh In On Connect Biopharma

Large investors have recently modified their holdings of the company. Choreo LLC acquired a new position in Connect Biopharma in the fourth quarter valued at $204,000. Callan Capital LLC raised its position in shares of Connect Biopharma by 91.3% in the 4th quarter. Callan Capital LLC now owns 80,000 shares of the company’s stock worth $110,000 after acquiring an additional 38,177 shares in the last quarter. Finally, Catalina Capital Group LLC acquired a new position in shares of Connect Biopharma in the 4th quarter valued at about $66,000. 58.72% of the stock is currently owned by institutional investors and hedge funds.

Connect Biopharma Company Profile

Connect Biopharma Holdings Limited, a clinical-stage biopharmaceutical company, engages in the development of therapies for the treatment of T cell-driven inflammatory diseases. The company is building a pipeline of small molecules and antibodies using functional T cell assays to screen and discover potent product candidates against validated immune targets.